300765 石药创新
已收盘 10-12 15:00:00
资讯
新帖
简况
石药创新（300765）10月8日主力资金净卖出945.42万元
证券之星 · 10-09
石药创新（300765）10月8日主力资金净卖出945.42万元
石药创新(300765.SZ)子公司SYS6002在2026年国际妇科肿瘤学会全球年会公布研究成果
智通财经 · 10-08
石药创新(300765.SZ)子公司SYS6002在2026年国际妇科肿瘤学会全球年会公布研究成果
石药创新（300765）9月30日主力资金净卖出695.34万元
证券之星 · 10-08
石药创新（300765）9月30日主力资金净卖出695.34万元
石药创新：截至2026年9月10日股东数为33,445户
证券之星 · 10-01
石药创新：截至2026年9月10日股东数为33,445户
9月30日石药创新涨7.06%，工银前沿医疗股票A基金重仓该股
证券之星 · 09-30
9月30日石药创新涨7.06%，工银前沿医疗股票A基金重仓该股
9月24日石药创新跌6.36%，工银前沿医疗股票A基金重仓该股
证券之星 · 09-24
9月24日石药创新跌6.36%，工银前沿医疗股票A基金重仓该股
9月21日石药创新涨5.72%，工银前沿医疗股票A基金重仓该股
证券之星 · 09-21
9月21日石药创新涨5.72%，工银前沿医疗股票A基金重仓该股
石药创新：9月16日召开业绩说明会，投资者参与
证券之星 · 09-17
石药创新：9月16日召开业绩说明会，投资者参与
研报掘金丨东吴证券：维持石药创新“买入”评级，创新管线进入密集收获期
格隆汇 · 09-16
研报掘金丨东吴证券：维持石药创新“买入”评级，创新管线进入密集收获期
石药创新：SYS6010再获突破性治疗认定 III期临床试验正在开展
同花顺 · 09-15
石药创新：SYS6010再获突破性治疗认定 III期临床试验正在开展
石药创新：SYS6010纳入突破性治疗品种名单
格隆汇 · 09-15
石药创新：SYS6010纳入突破性治疗品种名单
石药创新：控股子公司SYS6010肺癌研究成果公布
同花顺 · 09-14
石药创新：控股子公司SYS6010肺癌研究成果公布
石药创新：关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会的公告
同花顺 · 09-11
石药创新：关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会的公告
9月9日石药创新跌7.58%，工银前沿医疗股票A基金重仓该股
证券之星 · 09-09
9月9日石药创新跌7.58%，工银前沿医疗股票A基金重仓该股
燕文物流、爱士惟等公司香港IPO获中国证监会接收材料
同花顺 · 09-04
燕文物流、爱士惟等公司香港IPO获中国证监会接收材料
石药创新（300765）披露控股子公司SYS6010纳入突破性治疗品种名单用于治疗复发或转移性头颈鳞癌患者，9月2日股价下跌0.09%
证券之星 · 09-02
石药创新（300765）披露控股子公司SYS6010纳入突破性治疗品种名单用于治疗复发或转移性头颈鳞癌患者，9月2日股价下跌0.09%
石药创新(300765.SZ)子公司SYS6010纳入突破性治疗品种名单
智通财经 · 09-01
石药创新(300765.SZ)子公司SYS6010纳入突破性治疗品种名单
股市必读：石药创新（300765）8月28日董秘有最新回复
证券之星 · 08-31
股市必读：石药创新（300765）8月28日董秘有最新回复
石药创新：公司暂未布局流感相关药品
证券之星 · 08-28
石药创新：公司暂未布局流感相关药品
石药创新：该产品于2025年9月取得临床试验批准通知书
证券之星 · 08-28
石药创新：该产品于2025年9月取得临床试验批准通知书
加载更多
公司概况
公司名称：
石药创新制药股份有限公司
所属行业：
食品制造业
上市日期：
2019-03-22
主营业务：
石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。
发行价格：
24.47
{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"石药创新","latestPrice":43.93,"timestamp":1791788601000,"preClose":45.4,"halted":0,"volume":10912228,"delay":0,"changeRate":-0.0324,"floatShares":1405000000,"shares":1405000000,"eps":0.7282,"marketStatus":"已收盘","change":-1.47,"latestTime":"10-12 15:00:00","open":45.57,"high":45.74,"low":43.4,"amount":482000000,"amplitude":0.0515,"askPrice":43.94,"askSize":65,"bidPrice":43.93,"bidSize":1185,"shortable":0,"etf":0,"ttmEps":0.7282,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791855000000},"marketStatusCode":5,"adr":0,"adjPreClose":45.4,"symbolType":"stock","openAndCloseTimeList":[[1791768600000,1791775800000],[1791781200000,1791788400000]],"highLimit":49.94,"lowLimit":40.86,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":16.2,"roa":"--","peRate":60.326833,"roe":"38.2%","epsLYR":-0.1731,"committee":0.277978,"marketValue":61704000000,"turnoverRate":0.0078,"status":1,"floatMarketCap":61704000000},"requestUrl":"/m/hq/s/300765","defaultTab":"news","newsList":[{"id":"2674188177","title":"石药创新（300765）10月8日主力资金净卖出945.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2674188177","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674188177?lang=zh_cn&edition=full","pubTime":"2026-10-09 09:19","pubTimestamp":1791508781,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月8日收盘，石药创新报收于45.1元，下跌4.43%，换手率1.03%，成交量14.49万手，成交额6.68亿元。10月8日的资金流向数据方面，主力资金净流出945.42万元，占总成交额1.42%，游资资金净流入553.14万元，占总成交额0.83%，散户资金净流入392.28万元，占总成交额0.59%。融券方面，融券卖出3.34万股，融券偿还6100.0股，融券余量11.27万股，融券余额508.48万元。石药创新主营业务：生物制药和功能食品及原料的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900007357.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673073502","title":"石药创新(300765.SZ)子公司SYS6002在2026年国际妇科肿瘤学会全球年会公布研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2673073502","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673073502?lang=zh_cn&edition=full","pubTime":"2026-10-08 17:49","pubTimestamp":1791452972,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新 发布公告，公司的控股子公司石药集团巨石生物制药有限公司在10月1日-10月3日于加拿大蒙特利尔举办的2026年国际妇科肿瘤学会全球年会中，以快速口头报告形式公布了SYS6002单药用于治疗晚期宫颈癌的I期临床研究数据。SYS6002是一种靶向Nectin-4的新一代抗体偶联药物。该药物采用酶催化定点抗体偶联技术，将有效的有丝分裂抑制剂MMAE定向作用于表达 Nectin-4 的癌细胞。未发生导致死亡的治疗相关不良事件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1504708.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CANC","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673492680","title":"石药创新（300765）9月30日主力资金净卖出695.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2673492680","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673492680?lang=zh_cn&edition=full","pubTime":"2026-10-08 09:02","pubTimestamp":1791421346,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月30日收盘，石药创新报收于47.19元，上涨7.06%，换手率1.53%，成交量21.52万手，成交额10.06亿元。9月30日的资金流向数据方面，主力资金净流出695.34万元，占总成交额0.69%，游资资金净流出5360.25万元，占总成交额5.33%，散户资金净流入6055.58万元，占总成交额6.02%。融券方面，融券卖出600.0股，融券偿还3.39万股，融券余量8.54万股，融券余额403.21万元。石药创新主营业务：生物制药和功能食品及原料的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800002858.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672366736","title":"石药创新：截至2026年9月10日股东数为33,445户","url":"https://stock-news.laohu8.com/highlight/detail?id=2672366736","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2672366736?lang=zh_cn&edition=full","pubTime":"2026-10-01 09:54","pubTimestamp":1790819644,"startTime":"0","endTime":"0","summary":"证券之星消息，石药创新(300765)10月01日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至9月10日的最新股东数？谢谢。石药创新回复：您好，感谢您对公司的关注，截至2026年9月10日，公司合并普通账户和融资融券信用账户股东数为33,445户，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100100002175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671272892","title":"9月30日石药创新涨7.06%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2671272892","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671272892?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:39","pubTimestamp":1790757591,"startTime":"0","endTime":"0","summary":"证券之星消息，9月30日石药创新涨7.06%，收盘报47.19元，换手率1.53%，成交量21.52万手，成交额10.06亿元。重仓石药创新的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共29家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026093000026096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","159891","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669463047","title":"9月24日石药创新跌6.36%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669463047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669463047?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:44","pubTimestamp":1790239481,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日石药创新跌6.36%，收盘报44.15元，换手率1.13%，成交量15.83万手，成交额7.11亿元。重仓石药创新的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共29家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669159100","title":"9月21日石药创新涨5.72%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669159100","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669159100?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:47","pubTimestamp":1789980424,"startTime":"0","endTime":"0","summary":"证券之星消息，9月21日石药创新涨5.72%，收盘报46.39元，换手率1.87%，成交量26.21万手，成交额12.11亿元。重仓石药创新的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共29家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092100021037.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668953006","title":"石药创新：9月16日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2668953006","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668953006?lang=zh_cn&edition=full","pubTime":"2026-09-17 12:06","pubTimestamp":1789617996,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月17日石药创新发布公告称公司于2026年9月16日召开业绩说明会。具体内容如下：300765石药创新投资者关系管理信息20260916。公告详情请查看附件石药创新主营业务：生物制药和功能食品及原料的研发、生产和销售。该股最近90天内共有3家机构给出评级，买入评级3家。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700016213.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667608835","title":"研报掘金丨东吴证券：维持石药创新“买入”评级，创新管线进入密集收获期","url":"https://stock-news.laohu8.com/highlight/detail?id=2667608835","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667608835?lang=zh_cn&edition=full","pubTime":"2026-09-16 14:49","pubTimestamp":1789541344,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0183","601555","BK0009","BK0188","BK0226","BK0028","BK0276","300765","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667264193","title":"石药创新：SYS6010再获突破性治疗认定 III期临床试验正在开展","url":"https://stock-news.laohu8.com/highlight/detail?id=2667264193","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667264193?lang=zh_cn&edition=full","pubTime":"2026-09-15 19:08","pubTimestamp":1789470480,"startTime":"0","endTime":"0","summary":"中证智能财讯石药创新(300765)9月15日晚间公告，公司控股子公司石药集团巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，拟定适应症为免疫及含 ...","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260915/c679932866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["300765","PSYK","MDTX","BMED","IBBJ","BK0226","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667610909","title":"石药创新：SYS6010纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2667610909","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667610909?lang=zh_cn&edition=full","pubTime":"2026-09-15 16:34","pubTimestamp":1789461242,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667628659","title":"石药创新：控股子公司SYS6010肺癌研究成果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2667628659","media":"同花顺","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667628659?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:22","pubTimestamp":1789374120,"startTime":"0","endTime":"0","summary":"9月14日，石药创新(300765.SZ)公告称，公司控股子公司巨石生物在2026年世界肺癌大会上，以口头报告形式公布SYS6010联合恩朗苏拜单抗I/II期临床研究数据。SYS6010为巨石生物自主研发的EGFR靶 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260914/c679879866.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260914/c679879866.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666522033","title":"石药创新：关于参加2026年河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2666522033","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666522033?lang=zh_cn&edition=full","pubTime":"2026-09-11 21:01","pubTimestamp":1789131660,"startTime":"0","endTime":"0","summary":" 证券日报网讯9月11日，石药创新发布公告称，公司将参加“2026年度河北辖区上市公司投资者网上集体接待日暨2026年半年报业绩说明会活动”，活动时间为2026年9月16日 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260911/c679842541.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260911/c679842541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666058631","title":"9月9日石药创新跌7.58%，工银前沿医疗股票A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666058631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666058631?lang=zh_cn&edition=full","pubTime":"2026-09-09 16:39","pubTimestamp":1788943143,"startTime":"0","endTime":"0","summary":"证券之星消息，9月9日石药创新跌7.58%，收盘报41.72元，换手率2.02%，成交量28.37万手，成交额12.42亿元。重仓石药创新的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共29家，其中持有数量最多的公募基金为工银瑞信基金的工银前沿医疗股票A。工银前沿医疗股票A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900027793.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159891","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664539339","title":"燕文物流、爱士惟等公司香港IPO获中国证监会接收材料","url":"https://stock-news.laohu8.com/highlight/detail?id=2664539339","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664539339?lang=zh_cn&edition=full","pubTime":"2026-09-04 19:04","pubTimestamp":1788519840,"startTime":"0","endTime":"0","summary":"9月4日，中国证监会发布《境内企业境外发行证券和上市备案情况表(首次公开发行及全流通)(截至2026年9月4日)》。其中，燕文物流、爱士惟、智租物联、灵卡科技、石药创新(300765.SZ)、清明上 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260904/c679615949.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260904/c679615949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0158","BK0188","300765","BK0078","688403","BK0214","BK0012","BK0069","BK0130","BK0028","BK0224","601126","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664890915","title":"石药创新（300765）披露控股子公司SYS6010纳入突破性治疗品种名单用于治疗复发或转移性头颈鳞癌患者，9月2日股价下跌0.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664890915","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664890915?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:27","pubTimestamp":1788341259,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，石药创新报收于44.5元，较前一交易日下跌0.09%，最新总市值为625.04亿元。近日，石药创新制药股份有限公司发布公告称，其控股子公司巨石生物开发的SYS6010被国家药品监督管理局药品审评中心纳入突破性治疗品种名单，适用于经免疫和含铂化疗治疗失败的复发或转移性头颈鳞癌患者。SYS6010是一款靶向EGFR的抗体偶联药物，目前关键III期临床试验正在进行中。此前该药物已获两项突破性治疗认定，分别针对非小细胞肺癌和食管鳞癌。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200030925.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664373388","title":"石药创新(300765.SZ)子公司SYS6010纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2664373388","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664373388?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:14","pubTimestamp":1788254043,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药创新(300765.SZ)发布公告，公司控股子公司石药集团巨石生物制药有限公司开发的SYS6010被国家药品监督管理局药品审评中心(简称“药审中心”)纳入突破性治疗品种名单。该药品拟定适应症(或功能主治)为：经免疫和含铂化疗治疗失败的复发或转移性头颈鳞癌(R/M HNSCC)患者。公告显示，此前，SYS6010已获得药审中心授予的2项突破性治疗认定(不含此次)，拟定适应症分别为：单药用于经EGFR-TKI和含铂化疗治疗失败的EGFR突变阳性晚期非小细胞肺癌(NSCLC);既往一线接受含铂化疗和免疫检查点抑制剂(ICI)治疗后失败的不可切除的局部晚期或转移性食管鳞癌。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490381.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石药创新(300765.SZ)子公司SYS6010纳入突破性治疗品种名单","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663569042","title":"股市必读：石药创新（300765）8月28日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2663569042","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663569042?lang=zh_cn&edition=full","pubTime":"2026-08-31 01:10","pubTimestamp":1788109817,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，石药创新报收于44.4元，下跌5.43%，换手率1.86%，成交量26.12万手，成交额11.86亿元。投资者： 请问贵司的仑卡奈单抗注射液目前临床进程，以及上市计划董秘： 您好，感谢您对公司的关注，该产品于2025 年 9 月取得临床试验批准通知书，后续进展请留意公司公告，谢谢。董秘： 您好，感谢您对公司的关注，截至2026年8月20日，公司合并普通账户和融资融券信用账户股东数为33,821户，谢谢！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100000563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662063660","title":"石药创新：公司暂未布局流感相关药品","url":"https://stock-news.laohu8.com/highlight/detail?id=2662063660","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662063660?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:09","pubTimestamp":1787908147,"startTime":"0","endTime":"0","summary":"证券之星消息，石药创新(300765)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问：贵司研发的创新药品或疫苗、目前有针对流感领域的药品吗？石药创新回复：您好，感谢您对公司的关注，公司暂未布局流感相关药品，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800039260.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662633080","title":"石药创新：该产品于2025年9月取得临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2662633080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662633080?lang=zh_cn&edition=full","pubTime":"2026-08-28 17:00","pubTimestamp":1787907627,"startTime":"0","endTime":"0","summary":"证券之星消息，石药创新(300765)08月28日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司的仑卡奈单抗注射液目前临床进程，以及上市计划石药创新回复：您好，感谢您对公司的关注，该产品于2025 年 9 月取得临床试验批准通知书，后续进展请留意公司公告，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082800038955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1791806813184,"stockEarnings":[{"period":"1week","weight":-0.0379},{"period":"1month","weight":0.0882},{"period":"3month","weight":0.1731},{"period":"6month","weight":0.3926},{"period":"1year","weight":0.026},{"period":"ytd","weight":0.2587}],"compareEarnings":[{"period":"1week","weight":-0.0074},{"period":"1month","weight":-0.0349},{"period":"3month","weight":-0.0456},{"period":"6month","weight":-0.0433},{"period":"1year","weight":-0.0305},{"period":"ytd","weight":-0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"33445人(较上一季度减少1.11%)","perCapita":"41997股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":" 石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药创新,300765,石药创新股票,石药创新股票老虎,石药创新股票老虎国际,石药创新行情,石药创新股票行情,石药创新股价,石药创新股市,石药创新股票价格,石药创新股票交易,石药创新股票购买,石药创新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药创新(300765)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药创新(300765)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}